CorMedix Inc. (CRMD)
2025-03-31 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Net sales | 39,081,657 | 11,456,115 | 806,119 | |
| Cost of sales | 1,596,715 | 686,598 | 509,839 | |
| Gross profit (loss) | 37,484,942 | 10,769,517 | 296,280 | |
| Selling and marketing | 4,473,840 | 6,748,900 | 7,386,841 | |
| Research and development | 3,192,440 | 727,119 | 650,988 | |
| General and administrative | 9,693,382 | 6,580,834 | 7,559,277 | |
| Total operating expenses | 17,359,662 | 14,056,853 | 15,597,106 | |
| Income (loss) from operations | 20,125,280 | -3,287,336 | -15,300,826 | |
| Interest income | 566,797 | 553,856 | - | |
| Interest expense | 10,007 | 10,007 | - | |
| Foreign exchange transaction (loss) gain | -38,172 | -33,325 | -1,473 | |
| Total other income | 518,618 | 510,524 | - | |
| Other income | - | - | 500,000 | |
| Interest income, other | - | - | 657,366 | |
| Interest expense, operating and nonoperating | - | - | 6,556 | |
| Other nonoperating income (expense) | - | - | 1,149,337 | |
| Net income (loss) before income taxes | 20,643,898 | -2,776,812 | -14,151,489 | |
| Net income (loss) | 20,643,898 | -2,776,812 | -14,151,489 | |
| Unrealized loss from investment | -4,511 | 5,040 | 2,030 | |
| Foreign currency translation (loss) gain | -1,579 | -1,651 | - | |
| Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent | - | - | 240 | |
| Other comprehensive income (loss), net of tax | - | 3,389 | 2,270 | |
| Total other comprehensive loss | -6,090 | -2,773,423 | -14,149,219 | |
| Other comprehensive income (loss) | -20,637,808 | -2,773,423 | -14,149,219 | |
| Basic eps | 0.32 | -0.05 | -0.25 | |
| Diluted eps | 0.3 | -0.05 | -0.25 | |
| Basic average shares | 65,244,341 | 58,825,221 | 57,620,974 | |
| Diluted average shares | 68,975,418 | 58,825,221 | 57,620,974 | |